"Investigation of the Relationship Between New Coronary Virus Disease (COVID-19) and Anxiety and Depressive Symptoms in Pregnant Women"

''(COVID-19) and Anxiety and Depressive Symptoms in Pregnant Women"

In our study; Anxiety and depression levels, socio-demographic characteristics of the pregnant women who were admitted to our hospital between 25.04.2020-25.07.2020 and treated with the diagnosis of covid 19, and the change in anxiety and depression levelsWİTH Beck Depression and Anxiety Score after the disease regressed are planned.

(Beck depression scale contains 10 questions and a total of 1 to 100 points is obtained. High score indicates that depression and anxiety are high.) 0-16 points = mild depressive symptoms

17-29 points = moderate depressive symptoms

30-63 points = severe depressive symptoms

Study Overview

• Status: Completed
• Conditions: Depression, Postpartum; Anxiety; COVID
• Intervention / Treatment: Behavioral: covid-19 positive pregnant women

Detailed Description

The sociodemographic data form prepared by the researchers will be filled out by interviewing the patients who are willing to participate in the study. In addition, Beck Depression Scale, Beck Anxiety Scale, State and Trait Anxiety Scale will be given by the participants themselves. When the patients come to their first control after discharge, the scales specified will be repeated.

• Study Type: Observational
• Enrollment (Actual): 100

Contacts and Locations

Study Locations

• Turkey
  • İ̇stanbul
    • Istanbul, İ̇stanbul, Turkey, 34000
      • Pinar Yalcin Bahat

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: Female

• Sampling Method: Probability Sample

Study Population

Pregnant women with a positive covid -19 pcr test between the ages of 18 and 45 will be included in the study and beck and anxiety tests will be performed 3 months after birth.

Description

Inclusion Criteria:

• covid -19 pcr positive pregnant women
• no psychiatric diagnosis no use of psychiatric medicine

Exclusion Criteria:

Non-pregnant patients, A psychiatric diagnosis use of psychiatric medicine

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluation of depression and anxiety score changes of covid-19 positive pregnants	Evaluation of depression and anxiety score changes of covid-19 positive pregnants Pregnant women are questioned how this period was affected, as the pandemic period loaded with extra stress and caused depression and anxiety.	4 months

Collaborators and Investigators

• Sponsor: Kanuni Sultan Suleyman Training and Research Hospital
• Collaborators: Ayşegül Bestel; İbrahim Polat; Merve Aldıkaçtıoğlu Talmaç

Study record dates

Study Major Dates

• Study Start (ACTUAL): April 25, 2020
• Primary Completion (ACTUAL): August 25, 2020
• Study Completion (ACTUAL): August 26, 2020

Study Registration Dates

• First Submitted: May 11, 2020
• First Submitted That Met QC Criteria: May 11, 2020
• First Posted (ACTUAL): May 12, 2020

Study Record Updates

• Last Update Posted (ACTUAL): September 2, 2020
• Last Update Submitted That Met QC Criteria: August 31, 2020
• Last Verified: May 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Behavioral Symptoms; Mental Disorders; Mood Disorders; Pregnancy Complications; Puerperal Disorders; Depressive Disorder; Depression; Anxiety Disorders; Depression, Postpartum
• Other Study ID Numbers: beckcovid

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No